An engaged and accountable leadership team with a clear vision for NANETS is critical for the success, growth, and long-term health of our organization.

Over the next few months, the NANETS board, advisory board, and nominating committee will be elected by the NANETS professional membership.

The NANETS Community would like to celebrate the life of Edda Gomez-Panzani, who passed on June 30, 2015.

novartis logoOn May 21, 2015 Novartis announced that the Phase III study of AfinitorĀ® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care. The RADIANT-4 study is part of one of the largest clinical trial programs in NET.

"We look forward to presenting the findings from the RADIANT-4 trial of everolimus, which has the potential to become an important treatment option for patients with advanced nonfunctional GI or lung NET," said Alessandro Riva, MD, Global Head, Novartis Oncology Development and Medical Affairs. "The results will serve as the basis of planned worldwide regulatory filings for everolimus in these two types of NET, bringing us closer to our goal of offering Afinitor for these patients." (Source: Company website)

To read more, visit the Novartis website.